|
Código del ensayo EMN39 |
|
Ensayo A randomized, open-label, controlled phase 3 study comparing daratumumab, lenalidomide and dexamethasone induction followed by linvoseltamab versus continued daratumumab, lenalidomide, and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients |
|
Estado |
|
Localización Tumoral Hematológicos |
|
Tipo de tumor Mielomas |
|
Tipo de ensayo |
|
Tipo de tratamiento |
|
Situación clínica |
|
Centro |
